Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Finished Goods (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Finished Goods for 4 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 25.53% to $11.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Dec 2025, up 25.53% year-over-year, with the annual reading at $11.3 million for FY2025, 25.53% up from the prior year.
  • Finished Goods hit $11.3 million in Q4 2025 for Axsome Therapeutics, up from $10.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $11.3 million in Q4 2025 to a low of $1.6 million in Q4 2022.
  • Historically, Finished Goods has averaged $8.1 million across 4 years, with a median of $8.9 million in 2024.
  • Biggest five-year swings in Finished Goods: skyrocketed 506.48% in 2023 and later decreased 12.0% in 2025.
  • Year by year, Finished Goods stood at $1.6 million in 2022, then surged by 506.48% to $9.6 million in 2023, then fell by 6.81% to $9.0 million in 2024, then rose by 25.53% to $11.3 million in 2025.
  • Business Quant data shows Finished Goods for AXSM at $11.3 million in Q4 2025, $10.3 million in Q3 2025, and $9.5 million in Q2 2025.